Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the 3rd conference on European Reference Networks in Lithuania, EuroBloodNet was officially awarded as one of the recently approved ERNs.

Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017…

EHA is an active member of the Alliance for Biomedical Research in Europe (BioMed Alliance), in which Europe’s leading medical societies have joined forces to represent the interests of over 400,000 researchers and health professionals.

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient…

EHA is entering the next phase of its Hematology Awareness Campaign this fall. Face-to-face meetings will be conducted with EU institutions and other relevant stakeholders in Brussels, to raise awareness in hematology, increase the visibility of EHA, advocate key EHA positions, contribute to important policy debates and build relationships and alliances.

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Historical survival for patients 18-45 years with ALL is approximately 40 %.

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.